2 results
Approved WMOCompleted
The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by a regimen including an alirocumab starting dose of 150 mg Q4W as add-on to non-statin lipid modifying background therapy or as…
Approved WMOCompleted
The primary objective is the degree of IOP lowering after trabeculectomy with adjuvant Ologen® implantation, in comparison to trabeculectomy with mitomycin-C. Secondary objectives are peroperative and postoperative complications, and postoperative…